Company news

Exelixis, Inc. news in 2023

Exelixis, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

December 6, 2023

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

December 3, 2023

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

December 3, 2023

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

November 20, 2023

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

November 9, 2023

Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

October 21, 2023

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

October 17, 2023

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

September 11, 2023

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 23, 2023

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

August 22, 2023

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

August 20, 2023

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 31, 2023

Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.

July 22, 2023

Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

July 17, 2023

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June

May 29, 2023

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

May 6, 2023

Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023

May 2, 2023

Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders

April 30, 2023

Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

April 24, 2023

Exelixis Advances Board Refreshment Plan

April 12, 2023

Exelixis Reiterates Commitment to Shareholder Value Creation

April 4, 2023

Exelixis Announces $550 Million Share Repurchase Program

March 19, 2023

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

March 12, 2023

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

March 1, 2023

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

February 12, 2023

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 6, 2023

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 23, 2023

Exelixis Announces Update on Patent Litigation with MSN Laboratories

January 18, 2023

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

January 7, 2023

Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —

January 2, 2023

Calls in 2023

Decks in 2023